KRAS and colorectal carcinoma: KY1022 effectively inhibited the growth of SW480 and LoVo CRC cells harboring APC and K-Ras mutations (Figure 3A and 3B) and reduced level of proliferating cell nuclear antigen (PCNA) (Figure 3C).